Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The RECOVERY-SIRIO randomized trial

BACKGROUND: Ion channel inhibition may offer protection against coronavirus disease 2019 (COVID-19). Inflammation and reduced platelet count occur during COVID-19 but precise quantification of risk thresholds is unclear. The Recovery-SIRIO study aimed to assess clinical effects of amiodarone and ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarese, Eliano P., Podhajski, Przemysław, Andreotti, Felicita, La Torre, Giuseppe, Gajda, Robert, Radziwanowski, Adrian, Nowicka, Małgorzata, Bukowski, Paweł, Gajda, Jacek, Omyła, Maciej, Lackowski, Piotr, Piasecki, Maciej, Jasiewicz, Małgorzata, Szymański, Paweł, Pietrzykowski, Łukasz, Michalski, Piotr, Kubica, Aldona, Urbanowicz, Iwona, Orsini, Nicola, Conte, Max, Pinkas, Jarosław, Brouwer, Marc A., Kubica, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2022
Materias:
COVID-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550324/
https://www.ncbi.nlm.nih.gov/pubmed/35912711
http://dx.doi.org/10.5603/CJ.a2022.0072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550324/
https://www.ncbi.nlm.nih.gov/pubmed/35912711
http://dx.doi.org/10.5603/CJ.a2022.0072

Ejemplares similares